Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

gastrointestinal therapeutics

- PMLiVE

Takeda offloads select portfolio to Acino ahead of Shire takeover

Hopes to reduce debt before acquistion completion

- PMLiVE

Johnson & Johnson agrees $20.4m settlement in Ohio over opioid crisis

Will avoid upcoming federal trial as a result

- PMLiVE

J&J puts pressure on rivals with new Erleada okay in prostate cancer

FDA previously granted priority review in this indication

- PMLiVE

Takeda’s HAE drug Takhzyro backed by NICE

New treatment option for rare, hereditary disease

- PMLiVE

J&J’s Tremfya filed for approval in US for psoriatic arthritis

Seeking share of increasingly competitive psoriasis market

- PMLiVE

AbbVie/Allergan’s merger faces public opposition

Advocacy groups and unions in the US express concerns

- PMLiVE

J&J’s ponesimiod tops Aubagio in head-to-head MS trial

Sets up regulatory filings and possible approval next year

- PMLiVE

Strike three for Rova-T has AbbVie cutting its losses

Will funnel R&D money into more promising projects

- PMLiVE

J&J found liable in first opioid mis-marketing verdict

Oklahoma challenge a milestone, but company will appeal

- PMLiVE

AbbVie scores FDA approval for arthritis treatment upadacitinib

Could find it difficult to live up to Humira

- PMLiVE

Imbruvica gains expanded use in Europe

Rival Calquence receives accelerated review in US

- PMLiVE

Lilly psoriasis drug beats J&J’s Tremfya in head-to-head trial

Shifting expectations in psoriasis outcomes

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links